Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Paxlovid (nirmatrelvir/ritonavir) has received endorsement from several guidelines for treating COVID-19 in adults, but its use in children is still uncertain.
Objectives: This study aimed to evaluate the safety and effectiveness of paxlovid in pediatric patients in the pediatric intensive care unit (PICU).
Methods: A retrospective analysis was performed on children with COVID-19. The children who received paxlovid comprised the paxlovid group; otherwise, they were referred to as the control group.
Results: A total of 31 children were enrolled, with 12 and 19 participants assigned to the paxlovid and control groups, respectively. Approximately 35% had received vaccination against the novel coronavirus. The control group exhibited a significantly lower mean age in comparison to the paxlovid group (p < 0.001). However, no significant differences were observed between the groups in terms of other baseline data and biochemical indexes at admission. However, on the fifth day of drug administration, the paxlovid group exhibited a statistically significant decrease in temperature compared to the control group (p < 0.05). Additionally, the paxlovid group exhibited a significantly shorter conversion time to negativity for novel coronary genes in the respiratory tract (9.5 days) compared to the control group (16 days, p < 0.05). The administration of paxlovid did not result in any observed adverse reactions. Merely two patients exhibited a transient elevation in liver enzyme levels.
Conclusion: The application of paxlovid in critically ill pediatric patients with COVID-19 can effectively control symptoms and promote virus clearance, demonstrating efficacy and a relatively low-risk profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0109298673313885240621110518 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation of the COVID-19 antiviral therapy Nirmatrelvir/Ritonavir (Paxlovid) across Canada in 2022: A qualitative analysis of key facilitating factors and challenges.
Can Commun Dis Rep
August 2025
Public Health Agency of Canada, Montréal, QC.
Background: The COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid, N/R) was approved for use in Canada in January 2022, with the Government of Canada assuming a procurement role and provinces, territories, and federal departments implementing usage within their respective healthcare systems. The objective of this analysis is to describe how N/R was implemented across various jurisdictions in the first six months after it was available for use and identify promising implementation practices.
Methods: Fourteen semi-structured discussions in small group settings were conducted with jurisdictional representatives involved in the implementation of N/R.
SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.
J Virol
August 2025
Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia, USA.
Roborovski dwarf hamsters are permissive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and progress to acute viral pneumonia with profound lung tissue injury, recapitulating hallmarks of severe coronavirus disease 2019 (COVID-19) in vulnerable patient groups such as older adults. In this study, we established dwarf hamster whole-body plethysmography and assessed disease severity and propensity for long-term compromise of lung recovery from severe COVID-19-like disease in young, adult, and aged animals. Aged dwarf hamsters infected intranasally with variant of concern (VOC) omicron BA.
View Article and Find Full Text PDFCanadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.
BMJ Open
August 2025
Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada
Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective. While effective vaccines and natural immunity have significantly reduced hospitalisations and the need for critical care, outpatient treatment options remain limited, and real-world evidence on their clinical and cost-effectiveness is lacking. In this paper, we present the design of the Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID).
View Article and Find Full Text PDFThe effect of monotherapy versus combination antiviral therapy on all-cause mortality risk in COVID-19 patients.
Diagn Microbiol Infect Dis
November 2025
NHC Key Laboratory of Pneumoconiosis, Shanxi Key Laboratory of Respiratory Diseases. Department of Pulmonary and Critical Care Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. Electronic address:
This study aimed to determine the effect of Azvudine and Paxlovid on COVID-19 prognosis. A retrospective investigation was conducted on 2,103 hospitalized patients from December 2022 to February 2023 at Shanxi Medical University's First Hospital. Patients were categorized into three groups based on their antiviral treatment: monotherapy, combination therapy, and no treatment.
View Article and Find Full Text PDFA cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries.
J Public Health Afr
June 2025
Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia.
Background: Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries.
Aim: This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three African countries.
Setting: The study was conducted using data from Ghana, Rwanda and Zambia.